"Dopamine Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
| Descriptor ID |
D015259
|
| MeSH Number(s) |
D27.505.519.625.150 D27.505.696.577.150
|
| Concept/Terms |
Dopamine Agents- Dopamine Agents
- Agents, Dopamine
- Dopaminergic Agents
- Agents, Dopaminergic
- Dopaminergic Drugs
- Drugs, Dopaminergic
- Dopamine Drugs
- Drugs, Dopamine
Dopamine Effect- Dopamine Effect
- Effect, Dopamine
- Dopaminergic Effect
- Effect, Dopaminergic
- Dopaminergic Effects
- Effects, Dopaminergic
- Dopamine Effects
- Effects, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agents".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agents".
This graph shows the total number of publications written about "Dopamine Agents" by people in this website by year, and whether "Dopamine Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Agents" by people in Profiles.
-
Assessing the benefits and risks of amantadine for irritability and aggression after traumatic brain injury. PM R. 2024 Jul; 16(7):661-668.
-
Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020 05; 127(5):843-850.
-
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
-
Distinct subthalamic coupling in the ON state describes motor performance in Parkinson's disease. Mov Disord. 2020 01; 35(1):91-100.
-
Interventions for cognitive problems in adults with brain cancer: A narrative review. Eur J Cancer Care (Engl). 2019 May; 28(3):e13088.
-
Dystonia. Nat Rev Dis Primers. 2018 09 20; 4(1):25.
-
Amantadine Did Not Positively Impact Cognition in Chronic Traumatic Brain Injury: A Multi-Site, Randomized, Controlled Trial. J Neurotrauma. 2018 10 01; 35(19):2298-2305.
-
Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study. J Neurotrauma. 2015 Aug 15; 32(16):1230-8.
-
Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry. 2015 Nov; 20(11):1406-19.
-
A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone. Drug Alcohol Depend. 2014 Mar 01; 136:100-7.